Ampersand sells Nexcelom Bioscience for $260m

Ampersand Capital Partners has sold Nexcelom Bioscience to PerkinElmer for $260 million.

25 June 2021•2 mins read
private equity deals, PE Hub
LinkedInXEmail
LinkedInXEmail

Related articles